ArticleInternational journal of molecular medicine2018
Anti-inflammatory effects of Lefty-1 in renal tubulointerstitial inflammation via regulation of the NF-κB pathway.
Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Immune-related core gene identification in irritable bowel syndrome and prediction of regulatory traditional Chinese medicines.Medicine · 2026Article
- A comparative transcriptomics analysis of mammalian and non-mammalian acute kidney injury (AKI) models.Frontiers in cell and developmental biology · 2025Article
- Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease.Experimental and therapeutic medicine · 2024Article
- Ginseng Saponin Rb1 Attenuates Cigarette Smoke Exposure-Induced Inflammation, Apoptosis and Oxidative Stress via Activating Nrf2 and Inhibiting NF-κB Signaling Pathways.International journal of chronic obstructive pulmonary disease · 2023Article
- The Molecular Mechanism of Renal Tubulointerstitial Inflammation Promoting Diabetic Nephropathy.International journal of nephrology and renovascular disease · 2023Review
- Lefty-1 inhibits renal epithelial-mesenchymal transition by antagonizing the TGF-β/Smad signaling pathway.Journal of molecular histology · 2020Article
- (Pro)renin receptor contributes to renal mitochondria dysfunction, apoptosis and fibrosis in diabetic mice.Scientific reports · 2019Article
- TGF-β1 promotes expression of fibrosis-related genes through the induction of histone variant H3.3 and histone chaperone HIRA.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal tubulointerstitial inflammation has an important role in fibrosis, which is the main pathogenetic alteration associated with chronic kidney disease (CKD). The left‑right determination factor 1 (Lefty‑1) gene pleiotropically and biologically regulates transforming growth factor, mitogen‑activated protein kinase and other signaling pathways, and is considered to have a potential anti‑inflammatory function. However, its role in renal tubulointerstitial inflammation, which is often a long‑term consequence of renal fibrosis, is currently unknown. In the present study, the effects of adenovirus‑mediated overexpression of Lefty‑1 (Ad‑Lefty‑1‑flag) on renal tubulointerstitial inflammation were determined using a mouse model of unilateral ureteral obstruction (UUO) and a rat renal tubular duct epithelial cell line (NRK‑52E), which was treated with lipopolysaccharide (LPS). In vivo results indicated that the inflammatory response was increased in UUO mice, as evidenced by the increase in inflammatory cytokines and chemokines. Conversely, Lefty‑1 significantly reversed the effects of UUO. Furthermore, the results of the in vitro study demonstrated that Lefty‑1 significantly inhibited LPS‑induced inflammatory marker expression in cultured NRK‑52E cells via the nuclear factor (NF)‑κB signaling pathway. These results suggested that Lefty‑1 may ameliorate renal tubulointerstitial inflammation by suppressing NF‑κB signaling. In conclusion, the findings of the present study indicated that Lefty‑1 may be considered a potential novel therapeutic agent for inhibiting renal tubulointerstitial inflammation or even reversing the CKD process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.